Miltenyi Biotec Sustainability Profile
Miltenyi Biotec, a leading global biotechnology company headquartered in Germany (DE), has been at the forefront of innovative cell and gene therapy solutions since its founding in 1989. With a strong presence in Europe, North America, and Asia, the company focuses on developing advanced technologies for biomedical research and clinical applications. Specialising in cell separation, cell culture, and gene editing, Miltenyi Biotec offers unique products such as the MACS® Technology and the CliniMACS® Prodigy system, which streamline workflows and enhance research outcomes. Renowned for its commitment to quality and innovation, the company has achieved significant milestones, including the development of cutting-edge tools that support personalised medicine. Miltenyi Biotec's dedication to advancing scientific knowledge has solidified its position as a trusted partner in the life sciences industry, making it a key player in the ongoing evolution of therapeutic solutions.
DitchCarbon Score
How does Miltenyi Biotec's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Miltenyi Biotec's score of 30 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Miltenyi Biotec's reported carbon emissions
Miltenyi Biotec, headquartered in Germany, has made significant commitments towards achieving net-zero carbon emissions by 2050. As of now, there is no specific emissions data available for the most recent year, indicating a lack of reported carbon emissions (in kg CO2e). However, the company is actively engaged in climate initiatives, having committed to the Science Based Targets initiative (SBTi) for net-zero emissions across all scopes. Miltenyi Biotec's net-zero commitment was established in 2023, with a long-term target set for 2050. This commitment reflects the company's dedication to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector. The absence of specific emissions data suggests that the company may still be in the process of establishing a comprehensive emissions inventory or reporting framework. Overall, Miltenyi Biotec's proactive stance on climate commitments positions it as a responsible player in the industry, aiming to align its operations with global climate goals.
How Carbon Intensive is Miltenyi Biotec's Industry?
How Carbon Intensive is Miltenyi Biotec's Location?
Miltenyi Biotec's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Miltenyi Biotec has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Singular Genomics Systems, Inc.
Menarini Silicon Biosystems, S.p.A.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.